CHESTERFIELD, United Kingdom, Nov. 10, 2015 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading specialty biopharmaceutical company, will present on Tuesday, Dec. 8, 2015, at the Oppenheimer 26th Annual Healthcare Conference at the Westin Grand Central, 212 E. 42nd St., in New York City. The conference is Dec. 8 and 9.
Mark Trudeau, President and Chief Executive Officer; Matt Harbaugh, Senior Vice President and Chief Financial Officer; and Cole Lannum, Senior Vice President of Investor Strategy and Investor Relations Officer, will represent the company in a session scheduled from 8:35 a.m. to 9:05 a.m. Eastern Time.
Individuals who cannot attend the meeting in person can find webcast information at: http://www.mallinckrodt.com/investors. A replay will also be available following the meeting.
ABOUT MALLINCKRODT Mallinckrodt is a global specialty biopharmaceutical and imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Investor Relations Coleman N. Lannum, CFA Senior Vice President, Investor Strategy and IRO 314-654-6649 firstname.lastname@example.org
Media Rhonda Sciarra Senior Manager, Communications 314-654-8618 email@example.com
Meredith Fischer Senior Vice President, Communications and Public Affairs 314-654-3318 firstname.lastname@example.org
SOURCE Mallinckrodt plc